Funder: ALS Association
Due Dates (Anticipated): December 2025 (Letter of Intent) | March 2026 (Full proposal, by invitation) | March 2026 (Letter of Intent) | June 2026 (Full proposal, by invitation)
Funding Amounts: Up to $500,000 total over 2 years; indirect costs capped at 10% of direct costs.
Summary: Supports preclinical assessment of new or repurposed ALS therapies, bridging research from laboratory to industry drug development.
Key Information: Two-step process: Letter of Intent required; full proposals by invitation only.